JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 27, 2006; DOI: 10.1124/jpet.106.110379


0022-3565/07/3201-229-235$20.00
JPET 320:229-235, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.110379v1
320/1/229    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Sheikh, A. A. K.
Right arrow Articles by Russel, F. G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Sheikh, A. A. K.
Right arrow Articles by Russel, F. G. M.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport

Azza A. K. El-Sheikh, Jeroen J. M. W. van den Heuvel, Jan B. Koenderink, and Frans G. M. Russel

Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands

Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases as well as malignancies. Especially at high MTX dosages, severe adverse effects with this combination may occur, usually resulting from an impaired renal elimination. It has been shown that the mechanism of this interaction cannot be fully attributed to inhibition of basolateral MTX uptake in renal proximal tubules. Here, we studied the effect of various NSAIDs on MTX transport in membrane vesicles isolated from cells overexpressing the proximal tubular apical efflux transporters human multidrug resistance protein (MRP) 2/ABCC2 and MRP4/ABCC4. MTX was transported by MRP2 and MRP4 with Km values of 480 ± 90 and 220 ± 70 µM, respectively. The inhibitory potency of the NSAIDs was generally higher against MRP4- than MRP2-mediated MTX transport, with therapeutically relevant IC50 values, ranging from approximately 2 µM to 1.8 mM. Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. In some cases, more complex interaction patterns were observed. Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model. Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration. Our data suggest that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential new site and mechanism contributing to the overall interaction between these drugs.


Received July 4, 2006; accepted September 26, 2006.

Address correspondence to: Dr. Frans G. M. Russel, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Department of Pharmacology and Toxicology 149, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: F.Russel{at}ncmls.ru.nl




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
R. M. Pelis, M. Shahidullah, S. Ghosh, M. Coca-Prados, S. H. Wright, and N. A. Delamere
Localization of Multidrug Resistance-Associated Protein 2 in the Nonpigmented Ciliary Epithelium of the Eye
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 479 - 485.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. S. Lagas, C. M. M. van der Kruijssen, K. van de Wetering, J. H. Beijnen, and A. H. Schinkel
Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone
Drug Metab. Dispos., January 1, 2009; 37(1): 129 - 136.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, E. Krieger, F. G. M. Russel, and J. B. Koenderink
Functional Role of Arginine 375 in Transmembrane Helix 6 of Multidrug Resistance Protein 4 (MRP4/ABCC4)
Mol. Pharmacol., October 1, 2008; 74(4): 964 - 971.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
K. Heredi-Szabo, E. Kis, E. Molnar, A. Gyorfi, and P. Krajcsi
Characterization of 5(6)-Carboxy-2,'7'-Dichlorofluorescein Transport by MRP2 and Utilization of this Substrate as a Fluorescent Surrogate for LTC4
J Biomol Screen, April 1, 2008; 13(4): 295 - 301.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
Z. P. Lin, Y.-L. Zhu, D. R. Johnson, K. P. Rice, T. Nottoli, B. C. Hains, J. McGrath, S. G. Waxman, and A. C. Sartorelli
Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response
Mol. Pharmacol., January 1, 2008; 73(1): 243 - 251.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama
Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1162 - 1170.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.